Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.

Who May Be Eligible (Plain English)

Who May Qualify: - White Brazilian of European descent - Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD - Eligibility to immediate-release MPH (IR-MPH) treatment Who Should NOT Join This Trial: - Contraindication for IR-MPH use - Current stimulant treatment - Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis) - Current or past history of psychosis - Estimated intelligence quotient score lower than 70 Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * White Brazilian of European descent * Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD * Eligibility to immediate-release MPH (IR-MPH) treatment Exclusion Criteria: * Contraindication for IR-MPH use * Current stimulant treatment * Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis) * Current or past history of psychosis * Estimated intelligence quotient score lower than 70

Treatments Being Tested

DRUG

Immediate-release Methylphenidate

Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects

Locations (1)

Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil